Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension

Abstract

The 3-year FREEDOM trial assessed the efficacy and safety of 60 mg denosumab every 6 months for the treatment of postmenopausal women with osteoporosis. Participants who completed the FREEDOM trial were eligible to enter an extension to continue the evaluation of denosumab efficacy and safety for up to 10 years. For the extension results presented here, women from the FREEDOM denosumab group had 2 more years of denosumab treatment (long-term group) and those from the FREEDOM placebo group had 2 years of denosumab exposure (cross-over group). We report results for bone turnover markers (BTMs), bone mineral density (BMD), fracture rates, and safety. A total of 4550 women enrolled in the extension (2343 long-term; 2207 cross-over). Reductions in BTMs were maintained (long-term group) or occurred rapidly (cross-over group) following denosumab administration. In the long-term group, lumbar spine and total hip BMD increased further, resulting in 5-year gains of 13.7% and 7.0%, respectively. In the cross-over group, BMD increased at the lumbar spine (7.7%) and total hip (4.0%) during the 2-year denosumab treatment. Yearly fracture incidences for both groups were below rates observed in the FREEDOM placebo group and below rates projected for a “virtual untreated twin” cohort. Adverse events did not increase with long-term denosumab administration. Two adverse events in the cross-over group were adjudicated as consistent with osteonecrosis of the jaw. Five-year denosumab treatment of women with postmenopausal osteoporosis maintained BTM reduction and increased BMD, and was associated with low fracture rates and a favorable risk/benefit profile. © 2012 American Society for Bone and Mineral Research

Shown for reading. Its publisher allows quoting it, not republishing it.

References 14

1. 1.

   Kostenuik PJ. Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr Opin Pharmacol. 2005;5:618-25.

   Not in our library10.1016/j.coph.2005.06.005

2. 2.

   Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423:337-42.

   Not in our library10.1038/nature01658

3. 3.

   Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756-65.

   Not in our library10.1056/nejmoa0809493

4. 4.

   Eastell R, Christiansen C, Grauer A, Kutilek S, Libanati C, McClung MR, Reid IR, Resch H, Siris E, Uebelhart D, Wang A, Weryha G, Cummings SR. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res. 2011;3:530-7.

   Not in our library10.1002/jbmr.251

5. 5.

   Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993;8:1137-48.

   Not in our library10.1002/jbmr.5650080915

6. 6.

   Thomas D, Carriere P, Jacobs I. Safety of denosumab in giant-cell tumour of bone. Lancet Oncol. 2010;11:815.

   Not in our library10.1016/s1470-2045(10)70170-4

7. 7.

   Longford NT. Random coefficient models. 1993.

   Not in our library

8. 8.

   Kenward MG, Roger JH. Small sample inference for fixed effects from restricted maximum likelihood. Biometrics. 1997;53:983-97.

   Not in our library

9. 9.

   Vittinghoff E, McCulloch CE, Woo C, Cummings SR. Estimating long-term effects of treatment from placebo-controlled trials with an extension period, using virtual twins. Stat Med. 2010;29:1127-36.

   Not in our library10.1002/sim.3870

10. 10.

    Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab. 2002;87:1586-92.

    Not in our library10.1210/jcem.87.4.8415

11. 11.

    Stein CM, Ray WA. The ethics of placebo in studies with fracture end points in osteoporosis. N Engl J Med. 2010;363:1367-70.

    Not in our library10.1056/nejmsb1006120

12. 12.

    Rosen CJ, Khosla S. Placebo-controlled trials in osteoporosis—proceeding with caution. N Engl J Med. 2010;363:1365-7.

    Not in our library10.1056/nejmsb1002227

13. 13.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

14. 14.

    Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350:1189-99.

    Not in our library10.1056/nejmoa030897

Cited by papers we hold 7

• Effect of drugs on bone mineral density in postmenopausal osteoporosis: a Bayesian network meta-analysis · 2021
  No notice
• Potential of biomarkers during pharmacological therapy setting for postmenopausal osteoporosis: a systematic review · 2021
  No notice
• RANKL signaling in bone marrow mesenchymal stem cells negatively regulates osteoblastic bone formation · 2018
  Corrected
• Clinical guidelines for the prevention and treatment of osteoporosis: summary statements and recommendations from the Italian Society for Orthopaedics and Traumatology · 2017
  No notice
• The Effect of Three or Six Years of Denosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the FREEDOM Extension · 2013
  No notice
• A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy · 2013
  No notice
• Denosumab: mechanism of action and clinical outcomes · 2012
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.